Premium
Novel therapeutics for metastatic renal cell carcinoma
Author(s) -
Hutson Thomas E.,
Figlin Robert A.
Publication year - 2009
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.24235
Subject(s) - temsirolimus , medicine , sorafenib , sunitinib , renal cell carcinoma , sunitinib malate , everolimus , bevacizumab , clinical trial , vascular endothelial growth factor , oncology , targeted therapy , kidney cancer , cancer , discovery and development of mtor inhibitors , vegf receptors , hepatocellular carcinoma , pi3k/akt/mtor pathway , chemotherapy , signal transduction , chemistry , biochemistry
The treatment of metastatic renal cell carcinoma (RCC) has changed dramatically during the past few years. Sunitinib malate, sorafenib tosylate, bevacizumab with interferon α, temsirolimus, and everolimus have improved clinical outcomes in randomized phase 3 trials by inhibiting the vascular endothelial growth factor and related pathways. Combinations and sequences of these agents are being evaluated. Other novel agents are in clinical development, some of which target novel pathways not yet exploited as therapy for RCC. Recently reported and ongoing clinical trials will help further define the role of these agents as therapy for metastatic RCC. Cancer 2009;115(10 suppl):2361‐7. © 2009 American Cancer Society.